Immatics N.V.
corporate_fare Company Profile
Immatics N.V. (NASDAQ:IMTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for IMTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-27, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for IMTX spans 4, SCHEDULE 13D/A, 6-K.
Recent high-impact activity:
- Perceptive Advisors Buys $7.5M of Immatics Shares at $8.69
- Perceptive Advisors Discloses 7.6% Stake in Immatics After $7.5M Offering Purchase
- Immatics Closes $150M Offering, Nets $161.1M With Full Underwriter Option
- Immatics Launches $150M Underwritten Offering, Diluting Existing Holders
- Immatics Q2 2026: SUPRAME Trial Redesign, Cash Runway into 2028, and Updated Clinical Data
Financial Snapshot
Insider Transactions
IMTX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.